Bladder Cancer Detection Kit Market: Current Analysis and Forecast (2022-2028)
Global Bladder Cancer Detection Kit Market is expected to grow at a significant rate of around 11% during the forecast period. This is mainly due to the increasing incidence of bladder cancer, increase in awareness about cancer and its available therapies, growing healthcare expenditure, and expanding smoking and tobacco consumption are anticipated to accelerate the market of the bladder cancer detection kit market. According to Globocan, the global burden of bladder cancer is significantly high, representing 3.0% of all new cancer diagnoses, 2.1% of all cancer deaths in 2020, and the 11thmost frequently diagnosed cancer worldwide. Hence, the government authorities are keenly observing the development of products related to bladder cancer detection kits. Furthermore, the growing focus of major players on different growth strategies such as research and development activities, and product approvals are further expected to increase the market. Thus, the growing focus and investment of key stakeholders in the research and development of technologically advanced bladder cancer detection kits is further expected to grow the market.
Cepheid, BIOSYNEX SA, Abbott Laboratories, EXACT Sciences Corporation, Abingdon Health PLC, Xiamen Biotime Biotechnology Co., Ltd., IDL Biotech AB, Alfa Scientific Designs, Biomerica Inc, Hologic Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
"Amongst technology, fluorescence in situ hybridization (FISH) category to witness significant CAGR during the forecast period”
Based on type, the market is segmented into fluorescence in situ hybridization (FISH), enzyme-linked immunosorbent assay (ELISA), and others. The fluorescence in situ hybridization (FISH) category witnessed a significant CAGR during the forecast period. This segment is expected to take the lead since it is a unique urine examination technology that uses fluorescent direct-tagged DNA probes to detect genetic abnormalities in urothelial cells detected in the urine.
"Amongst end user, the hospitals & clinics to hold a significant share in the market in 2020”
On the basis of end-user, the market is categorized into hospitals & clinics, diagnostic centre, home care, research centers, and others. Among these, the hospitals & clinics to hold a significant share in the market in 2020. The bladder cancer detection kit market in hospital infrastructure is being driven globally by innovations. Moreover, The investor building cancer detection and treatment hospitals are leveraging the bladder cancer market.
"North America to hold a significant share in the market”
In 2020, North America held a significant share of the global bladder cancer detection kit market. This is mainly attributed to the rising prevalence of bladder cancer across the region is driving the North American bladder cancer detection kit market. According to the American Cancer Society, about 83,730 new cases of bladder cancer and approximately 17,200 deaths from bladder cancer occurred in the US in 2020. Moreover, The development of the bladder cancer detection kit market in these regions is anticipated to be supported further by increased R&D investments, bettering healthcare infrastructure, and more government initiatives. As the prevalence and mortality rate is rising worldwide, the demand for bladder cancer diagnosis is increasing. This further increases the investment in R&D of non-invasive bladder cancer detection products, hence driving the bladder cancer detection kit market growth.
Reasons to buy this report:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook